Build a Better Process
Stock Risk Measures for Taro Pharmaceutical Indus
A quantitative factor review as of September 30, 2021.
- Company Info - Description, identity and sector data.
- Share Data - Stock earnings and key dates.
- Market Risk - Beta, size, liquidity and momentum measures.
- Financial Risk - Earnings and dividends.
Updated: October 05, 2021
See how we arrive at an overall risk score of
for TARO below.
An ad-free and cookie-free website.
TARO Risk Report
Our quantitative data points are meant to provide a high-level understanding of
factors in equity risk models for Taro Pharmaceutical Indus. Portfolio managers use these
models to forecast risk, optimize portfolios and review performance.
We show how TARO stock compares to 2,000+ US-based stocks, and to
peers in the Manufacturing sector and Pharmaceutical Preparation Manufacturing industry.
Please do not consider this data as investment advice. Data is downloaded from
sources we deem reliable, but errors may occur.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
- Symbol: TARO
- FactorPad FPID: f36dcp
- SEC CIK: 0000906338
- Share Class FIGI: BBG001SDFY52
- Location: 14 Hakitor Street Po Box 10347, Haifa Israel
- Web: www.taro.com
Sector and Industry
- Sector: Manufacturing
- Industry: Pharmaceutical Preparation Manufacturing
- SIC Code: 2834
- Shares Outstanding: 37,926,044
Earnings and Dividends
- Trailing 12-month earnings: 0.77
- Next earnings date: 2021-10-27
- Dividend yield in last 12 months: 0%
- Ex-dividend date:
Market Risk Measures
Many of the following risk metrics are standardized and transformed into
quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest
rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs
in the market. (↑↑)
Beta: 0.72 |
Stocks with higher market capitalization often have lower risk. (↑↓)
Market Capitalization: $2,421,957,170 |
Higher average daily dollar volume over the past 30 days implies lower
liquidity risk. (↑↓)
Daily Dollar Volume: $852,387 |
Higher price momentum stocks, aka recent winners, equate to lower risk for many
Stock Price Change (1-Year): 17.39% |
Financial Risk Measures
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Earnings Yield (E/P): 1.22% |
Companies with higher dividend yields, if sustaintable, are perceived to
have lower risk. (↑↓)
Dividend Yield (D/P): 0% |
TARO stock risk
TARO PHARMACEUTICAL INDUS stock beta
TARO risk report
TARO risk analysis
TARO PHARMACEUTICAL INDUS credit risk
TARO liquidity risk
TARO systematic risk
TARO specific risk
TARO PHARMACEUTICAL INDUS volatility
TARO financial ratio
A newly-updated free resource. Connect and refer a friend today.